Inogen (NASDAQ:INGN) Announces Quarterly Earnings Results

Inogen (NASDAQ:INGN) released its quarterly earnings results on Tuesday. The medical technology company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.14, Briefing.com reports. Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The firm had revenue of $78.03 million for the quarter, compared to analysts’ expectations of $73.67 million. During the same quarter last year, the firm posted ($0.63) EPS. The company’s revenue was up 8.1% compared to the same quarter last year.

Inogen Stock Up 10.0 %

INGN traded up $0.73 on Wednesday, reaching $8.03. 464,579 shares of the company traded hands, compared to its average volume of 525,314. The company has a market cap of $189.11 million, a P/E ratio of -1.88 and a beta of 1.10. The firm has a fifty day simple moving average of $7.07 and a two-hundred day simple moving average of $6.50. Inogen has a one year low of $4.13 and a one year high of $11.98.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. William Blair upgraded shares of Inogen from a “market perform” rating to an “outperform” rating in a research report on Thursday, February 15th. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a research report on Wednesday. Finally, Stifel Nicolaus lifted their price target on Inogen from $6.00 to $7.00 and gave the stock a “hold” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.00.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.